(125 days)
Not Found
Not Found
No
The summary describes a nucleic acid probe test for detecting Neisseria gonorrhoeae, which is a standard laboratory diagnostic technique and does not mention any AI or ML components.
No
This device is a diagnostic test (in vitro qualitative detection) for Neisseria gonorrhoeae, not a therapy or treatment.
Yes
The product description explicitly states "to aid in the diagnosis of gonococcal urogenital disease."
No
The device is a diagnostic assay that utilizes target amplification and nucleic acid probes, which are physical components and laboratory processes, not solely software. It also mentions automated and semi-automated instrumentation (TIGRIS® DTS® Automated Analyzer), further indicating it is not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states that the assay is for the "in vitro qualitative detection of ribosomal RNA (rRNA) from Neisseria gonorrhoeae (GC) to aid in the diagnosis of gonococcal urogenital disease". The term "in vitro" means "in glass" or "in the lab," referring to tests performed outside of a living organism.
- Specimen Types: The assay is designed to test various biological specimens (swabs and urine) collected from individuals. This is characteristic of IVD tests, which analyze samples to provide information about a person's health.
- Purpose: The purpose is to "aid in the diagnosis of gonococcal urogenital disease," which is a diagnostic purpose.
Therefore, based on the provided information, the APTIMA® Assay for Neisseria gonorrhoeae clearly fits the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The APTIMA® Assay for Neisseria gonorrhoeae is a target amplification nucleic acid probe test that utilizes target capture for the in vitro qualitative detection of ribosomal RNA (rRNA) from Neisseria gonorrhoeae (GC) to aid in the diagnosis of gonococcal urogenital disease using the TIGRIS® DTS® Automated Analyzer or semi-automated instrumentation as specified. The assay may be used to test the following specimens from symptomatic individuals: clinician-collected endocervical, vaginal and male urethral swab specimens; and patient-collected female and male urine specimens. The assay may be used to test the following specimens from asymptomatic individuals: clinician-collected endocervical and vaginal swab specimens; and patient-collected vaginal swab specimens¹ and female and male urine specimens.
¹Patient-collected vaginal swab specimens are an option for screening women when a pelvic exam is not otherwise indicated. The vaginal swab specimen collection kit is not for home use.
Product codes
LSL
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
urogenital
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.3390
Neisseria spp. direct serological test reagents.(a)
Identification. Neisseria spp. direct serological test reagents are devices that consist of antigens and antisera used in serological tests to identifyNeisseria spp. from cultured isolates. Additionally, some of these reagents consist ofNeisseria spp. antisera conjugated with a fluorescent dye (immunofluorescent reagents) which may be used to detect the presence ofNeisseria spp. directly from clinical specimens. The identification aids in the diagnosis of disease caused by bacteria belonging to the genusNeisseria, such as epidemic cerebrospinal meningitis, meningococcal disease, and gonorrhea, and also provides epidemiological information on diseases caused by these microorganisms. The device does not include products for the detection of gonorrhea in humans by indirect methods, such as detection of antibodies or of oxidase produced by gonococcal organisms.(b)
Classification. Class II (performance standards).
0
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/0/Picture/1 description: The image shows a stylized, abstract symbol in black against a white background. It consists of three parallel, curved lines that appear to be connected at the left side. The lines have varying thicknesses and end in a flourish at the bottom, resembling a calligraphic design or a stylized representation of a bird in flight.
Public Heaith Service
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Mr. E. Joseph McMullen Associate Director, Regulatory Affairs Gen-Probe Incorporated 10210 Genetic Center Drive San Diego. CA 92121-4362
OCT - 4 2006
K061509 Re: K001509
Trade/Device Name: TIGRIS® DTS® GEN-PROBE® APTIMA Assay for Neisseria gonorrhoeae Regulation Number: 21 CFR 866.3390 Regulation Name: Neisseria spp. direct serological test reagents Regulatory Class: Class II Product Code: LSL Dated: September 25, 2006 Received: September 26. 2006
Dear Mr. Shea:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean r head be actived and itermination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
1
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally prarketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, n you stions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers. International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
Sally, attorn
Sally A. Hojvat, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
2
GEN-PROBE INCORPORATED
APTIMA Assay® for Neisseria gonorrhoeae – Special 510(k) TIGRIS DTS
INDICATIONS FOR USE STATEMENT
| 510(k) Number:
| (if known) | K061509 |
|---|---|
| Device Name: | TIGRIS® DTS® GEN-PROBE APTIMA Assay® for Neisseria |
| gonorrhoeae | |
| Indications for | |
| Use: | The APTIMA® Assay for Neisseria gonorrhoeae is a target |
| amplification nucleic acid probe test that utilizes target capture for | |
| the in vitro qualitative detection of ribosomal RNA (rRNA) from | |
| Neisseria gonorrhoeae (GC) to aid in the diagnosis of gonococcal | |
| urogenital disease using the TIGRIS® DTS® Automated Analyzer | |
| or semi-automated instrumentation as specified. The assay may be | |
| used to test the following specimens from symptomatic | |
| individuals: clinician-collected endocervical, vaginal and male | |
| urethral swab specimens; and patient-collected female and male | |
| urine specimens. The assay may be used to test the following | |
| specimens from asymptomatic individuals: clinician-collected | |
| endocervical and vaginal swab specimens; and patient-collected | |
| vaginal swab specimens¹ and female and male urine specimens. |
¹Patient-collected vaginal swab specimens are an option for screening women
when a pelvic exam is not otherwise indicated. The vaginal swab specimen
collection kit is not for home use. |
PAGE IF NEEDED
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use X (Per 21 CFR 801.109)
OR
sion Sign Off
Over-the-Counter Use__________________________________________________________________________________________________________________________________________________________
Division Sign-Off
Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) k 061509